Cerecin

Cerecin

Cerecin, formerly Accera, is a company that looks to develop therapeutic drugs for neurodegenerative diseases.

Cerecin produces Ketasyn which is a molecule for Alzheimer's, Parkinson's, and other age associated memory impairments. The company was founded by Mark Heiman, Samuel Henderson, and Steve Orndorff in 2001, in Denver, Colorado, United States.

The company looks to understand core molecular and cellular processes that contribute to brain development, plasticity, function, and aging.

As of 2020, Cerecin is developing Tricapilin. Tricapilin is an investigational drug for neurological conditions that is meant to assist with Alzheimer's Disease, migraines, Parkinson's Disease, and epilepsy's.

Some of the companies and partners the company works with includes DCB duchembio, Nestle Health Science, Nestle PURINA, wilmar, and EDB Singapore.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Accera Series D round
11,000,000
January 3, 2011
6,000,000
September 16, 2004
79,081,610
October 25, 2013
5 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Bruce Marimoto

VP of drug development

Charles Stacey

CEO

Jerris Knaisch

Finance

Judy Walker

CMO

Sam Henderson

CSO

Further reading

Title
Author
Link
Type
Date

Accera - Crunchbase Company Profile & Funding

Web

Cerecin | Innovative Brain Health Solutions

Web

Cerecin | Products and Pipeline

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Accera

Denver, Colorado, United States

Drug Development

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.